{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=23", "query": { "intervention": "lenalidomide", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 703, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T11:06:55.517Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07341867", "title": "Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Triple Negative Breast Cancer", "Duffy Blood Group, Chemokine Receptor Gene Mutation", "Duffy Blood Group, Chemokine Receptor Gene C.-67T>C" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "LENALIDOMIDE", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew Hantel, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-07-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07341867" }, { "nct_id": "NCT01241734", "title": "Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Revlimid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-10", "completion_date": "2015-09-22", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • Durham, North Carolina", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241734" }, { "nct_id": "NCT00460031", "title": "Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "ketoconazole", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 34, "start_date": "2006-09-01", "completion_date": "2010-08-31", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 6, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00460031" }, { "nct_id": "NCT05660967", "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 111, "start_date": "2023-03-06", "completion_date": "2026-06-10", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 1, "location_summary": "Waukesha, Wisconsin", "locations": [ { "city": "Waukesha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660967" }, { "nct_id": "NCT00415064", "title": "Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Perifosine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2006-12", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2012-07-06", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415064" }, { "nct_id": "NCT07605416", "title": "Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Leukemia" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Daratumumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Granulocyte Colony-Stimulating Factor", "type": "BIOLOGICAL" }, { "name": "Stem Cell Isolation", "type": "PROCEDURE" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Transthoracic Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 74, "start_date": "2027-04-20", "completion_date": "2032-11-06", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 10, "location_summary": "New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07605416" }, { "nct_id": "NCT01644799", "title": "Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Follicular Lymphoma" ], "interventions": [ { "name": "idelalisib", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-08-02", "completion_date": "2017-05", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • St Louis, Missouri + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644799" }, { "nct_id": "NCT01779167", "title": "Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2012-06", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01779167" }, { "nct_id": "NCT00294632", "title": "Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2006-02", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00294632" }, { "nct_id": "NCT04191616", "title": "Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 54, "start_date": "2020-08-06", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-25T11:06:55.517Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago Ridge", "state": "Illinois" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191616" } ] }